Abstract
The introduction of monoclonal antibodies in the treatment on non-Hodgkin´s lymphoma patients was the real milestone in the treatment of lymphoma. At this time most common used monoclonal antibody in routine practice is rituximab, less frequently alemtuzumab and 90Y ibritumomab tiuxetan.
The developments of other monoclonal antibodies (galiximab, bevacizumab, SGN40, otatumumab etc.) indicates that target biologic therapy should be one of the mainstays of treatment for lymphoma patients in 21st century.